In addition to the above, candidate therapeutic targets for tauopathies include tau truncation (Novak et al., 2018a), impairment of axonal transport (Combs et al., 2019), dysfunction of tau in the nucleus (Bukar Maina et al., 2016), and functional impairment of dendritic tau (Ittner and Ittner, 2018). This evidence concerns the gene MAPT and tauopathy.